Alexander M. Gold
Independent DirectorDr. Alexander M. Gold M.D., F.A.C.C., also known as Alex, is a Director at Mineralys Therapeutics, Inc. since June 13, 2024. He serves as Chief Medical Officer at Beren Therapeutics P.B.C. Dr. Gold served as Senior Vice President of Clinical Development at Portola Pharmaceuticals, Inc. from 2013 to October 2017. Dr. Gold is a cardiologist with experience leading the development, approval and commercialization of new therapies. He has held executive positions at several biopharmaceutical companies that targeted numerous therapeutic areas, including cardiometabolic, renal and inflammation. Dr. Gold served as Vice President and Head of clinical development at Reata Pharmaceuticals from 2012 to 2013. He led clinical development of novel drugs targeting advanced kidney disease, chronic inflammation and oxidative stress. Prior to Reata, he held a number of leadership positions at Astra Zeneca from 2001 to 2012, as Executive Director and Development Leader for Brilinta®, Crestor® and Onglyza®. In this capacity, he was responsible for clinical and strategic development activities in the United States, leading regulatory interactions with the Food and Drug Administration and leading scientific, regulatory and medical affairs. He held the role of Head Medical Officer at Sanifit-CSL. He originally joined as Chief Medical Officer and President of Sanifit Inc. in 2017, which was then acquired by Vifor Pharma in January 2022 and subsequently by CSL Ltd. in August 2022. Dr. Gold is an Adjunct Professor at Stanford University School of Medicine. He also led large global outcomes trials, including JUPITER. He led global cross functional teams responsible for development, regulatory and commercial strategy and execution. He published in peer reviewed journals, such as The Lancet, Circulation, Journal of the American Journal of Cardiology and Clinical Therapeutics. Dr. Gold is a board certified cardiologist. He completed his internship, residency and cardiology fellowship at Beth Israel Deaconess Hospital/Harvard Medical School and conducted translational and clinical research as a fellow in cardiovascular research at the Harvard Clinical Research Institute. He received a B.A. in biology from Brandeis University from 1989 to 1991 and an M.D. from Harvard Medical School from 1991 to 1995.
公司职务
- 公司名称Mineralys Therapeutics, Inc.股票代码MLYS职务Independent Director
